RT Journal Article
SR Electronic
T1 Short- and Long-term Outcomes of children hospitalized with COVID-19 or Influenza: results of the AUTCOV study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.08.28.24312702
DO 10.1101/2024.08.28.24312702
A1 Wagenlechner, Christine
A1 Wendt, Ralph
A1 Reichardt, Berthold
A1 Mildner, Michael
A1 Mascherbauer, Julia
A1 Aigner, Clemens
A1 Auer, Johann
A1 Ankersmit, Hendrik Jan
A1 Graf, Alexandra Christine
YR 2024
UL http://medrxiv.org/content/early/2024/08/28/2024.08.28.24312702.abstract
AB Background Recent literature gives different results on morbidity and mortality after COVID-19 as compared to Influenza hospitalized children and results of large, population based studies are scant. In this population-based study in Austria, we evaluated and compared the short- and long-term outcomes after COVID-19 or Influenza hospitalization and associations with their baseline drug profile.Methods Individual data were provided on children ≤ 18 years hospitalized with COVID-19 in the years 2020 and 2021 or Influenza in 2016 – 2021 as well as on age-, sex- and region-matched controls from the Austrian Health Insurance Funds. The primary outcome was time to hospital discharge. Secondary outcomes were in-hospital death, all-cause mortality and readmission to hospital due to any reason. The median follow-up time was 430 days (IQR: 245-552) in the COVID-19 and 1221 days (IQR: 881-1599) in the Influenza group.Results 1063 children were hospitalized due to COVID-19 and 2781 children due to Influenza in the study period. Children hospitalized due to COVID-19 or Influenza were more likely to have a larger disease burden as compared to the general population. Influenza hospitalized patients were observed to be generally younger and a larger percentage of polypharmacy than those with COVID-19. No significant difference in the time to hospital discharge was found between cohorts (HR: 1.22 [95%-CI: 0.97-1.55], p=0.093). The risk for readmission was significantly higher for Influenza (HR: 1.23 [95%-CI: 1.03-1.47], p=0.021). In-hospital mortality (0.94% vs. 0.22%, p=0.004) and long-term mortality (p=0.009) was significantly larger in COVID-19 patients. One-year mortality after hospitalization was estimated with 1.13% (CI: 0.49-1.77) in the COVID and 0.32% (CI: 0.11-0.53) in the Influenza group.Conclusion A general picture of COVID-19 being a milder disease compared to Influenza may not be drawn. No significant difference for time to hospital discharge was observed between cohorts but the risk of readmission was significantly larger in the Influenza group. Death rates of COVID-19 hospitalized children seem to be higher, however, the low number of severe events may limit the findings.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe work was funded by the working group ARGE Ankersmit, Laboratory for Cardiac and Thoracic Diagnosis and Regeneration at the Department of Thoracic Surgery at the Medical University of Vienna.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This retrospective, national population-based study adheres to the Declaration of Helsinki and was approved by the ethics committee of Lower Austria (GS1-EK-4/747-2021).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesData supporting the results presented in the study are available upon reasonable request to the corresponding author.